RECRUITING Phase 2 ClinicalTrials.gov

Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers

Sponsor: Genmab • ClinicalTrials.gov ID: NCT07539311

Registry updated: 2026-10-06

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This Phase 2 study will be conducted in different countries around the world with up to about 160 participants. The purpose of this study is to evaluate how well Rina-S works against GI cancers. The medication in this study is Rina-S monotherapy (by itself; no other cancer treatments). All participants will receive active drug; no one will be given placebo. Participation in the study will require visits to the study site(s). During site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, imaging/X-rays) to monitor whether the study treatment is safe and effective. The duration of the study will be different for every participant, but an average study duration of 22 months is expected for participants. This will include a treatment period (expected to last an average of 12 months), plus data collection periods before and after treatment. Participants will be asked to attend 1 to 5 visits at the study clinic for each cycle (duration of an individual cycle is 21 days). If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open.

Interventions

Rina-S (Biological)
Intravenous (IV) administration.

Eligibility criteria

Key Inclusion Criteria: • All study cohorts * Participant has histologically or cytologically confirmed GI cancer. * Participant has documented metastatic or unresectable disease, not amenable to treatment with curative intent. * Participant has measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 at baseline. * Participant must have radiological disease progression while on or after receiving the most recent regimen. * Participant has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Participant has life expectancy ≥3 months. * Participant must be able to provide a newly obtained or archival tissue sample. * Participant must have adequate organ and bone marrow function, per laboratory test results prior to Rina-S administration. Key Exclusion Criteria (all study cohorts): * Participant has clinically significant non-malignant gastrointestinal disorders, including but not limited to, diarrhea \> grade 1, ulcerative colitis, inflammatory bowel disease. * Participants with recent (up to 4 weeks) history of significant gastrointestinal bleeding, current cancer related ulcerations, fistula, abscess or recent perforation (within 4 to 6 weeks). * Participant has a past or current malignancy other than the inclusion diagnosis before the planned first dose of trial treatment, or any evidence of residual disease from a previously diagnosed malignancy. * Participants with newly identified or known unstable (eg, progressing brain metastases) or symptomatic central nervous system (CNS) metastases or history of carcinomatous meningitis (also known as leptomeningeal disease). * Prior treatment with topoisomerase-1 inhibitor containing antibody-drug conjugate (ADC). * Treatment with an anticancer agent within 28 days prior to the first dose of trial treatment. Note: Other protocol-defined Inclusion and Exclusion criteria may apply.

Conditions

Gastrointestinal Cancers

Locations

USC Norris Comprehensive Cancer Center — Los Angeles, California, United States
UCLA Hematology/Oncology, Santa Monica — Santa Monica, California, United States
University of Colorado Hospitak Anschutz — Aurora, Colorado, United States
Moffitt Cancer Center — Tampa, Florida, United States
START Midwest — Grand Rapids, Michigan, United States
Greco-Hainsworth Center for Research — Nashville, Tennessee, United States
START San Antonio — San Antonio, Texas, United States
St John of God Subiaco Hospital — Subiaco, Western Australia, Australia
Cancer Research SA Pty Ltd — Adelaide, Australia
CHU Brest Cavale Blanche — Brest, Brittany (Bretagne), France
Hôpital Saint-Antoine Onco Med — Paris, France
National Cancer Center Hospital East — Kashiwa, Chiba, Japan
Kanagawa Cancer Center — Yokohama, Kanagawa, Japan
The University of Osaka Hospital — Suita, Osaka, Japan
Cancer Institute Hospital of JFCR — Kōtoku, Tokyo-To, Japan
Samsung Medical Center — Seoul, South Korea
Hammersmith Hospital — London, Greater London, United Kingdom

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment